Status:
COMPLETED
Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers
Lead Sponsor:
Alvogen Korea
Conditions:
Healthy
Eligibility:
All Genders
20-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Bonviva (150mg Ibandronate, qd) after oral adminis...
Detailed Description
The number of patient is eighty-four. Patients were randomly assigned either a Bonviva tablet(150mg Ibandronate, qd) first, DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) Second ...
Eligibility Criteria
Inclusion
- 20 to 55 years of healthy volunteers
Exclusion
- Hypersensitivity Reaction about Ibandronate or other drugs(aspirin, antibiotics)
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT01429675
Start Date
August 1 2011
End Date
March 1 2012
Last Update
November 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea